申请人:Shionogi & Co., Ltd.
公开号:US20140187544A1
公开(公告)日:2014-07-03
The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I):
and the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2
, R
3
, R
4
, R
20
, R
21
, Q, Y
1
, Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.
本公开涉及氧肟取代的喹喔啉型哌啶化合物,例如公式(I)中的化合物及其药用可接受的盐和溶剂化合物,其中R1、R2、R3、R4、R20、R21、Q、Y1、Z、A、B和a如本文所定义;包含有效量氧肟取代的喹喔啉型哌啶化合物的组合物,以及治疗或预防疾病的方法,例如疼痛,包括向需要治疗的动物施用有效量的氧肟取代的喹喔啉型哌啶化合物。